Most in a small group of patients receiving a stem cell-based infusion no longer needed insulin, but the drug may not suit those with more manageable type 1 diabetes.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $440.87, denoting a -1.68% move from the preceding trading day.

Vertex Pharmaceuticals Inc. closed 15.20% short of its 52-week high of $519.88, which the company achieved on November 8th.

Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...

Related Beal, the Boston office of Related Cos., has topped out construction of Leiden Center II at Innovation Square, a 345,000-square-foot life sciences project in Boston. The 1.8-acre site is ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

Vertex Pharmaceuticals has been making quiet waves lately, popping up on investors’ radars like a biotech whack-a-mole. With ...